Aridis Pharmaceuticals, which is developing immunotherapies for antibiotic-resistant infections, raised $26 million by offering 2.0 million shares at $13, the low end of the range of $13 to $15. Aridis Pharmaceuticals plans to list on the Nasdaq under the symbol ARDS. Cantor Fitzgerald acted as a lead manager on the deal.
